Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced that it has expanded its ResponseDX: Lung™ genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer (NSCLC). These rearranged genes promote tumor cell growth and predict lack of benefit from therapies that inhibit EGF receptor (EGFR) activity1...
More...
More...